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atitis have been excluded. Moreover, HEV testing is not per-
formed to prevent blood transmission in developed countries.
We report here on the case of a patient with acute hepatitis while
receiving potentially hepatotoxic medications for autoimmune
disorders, with low-level autoimmune markers and negative
‘‘standard’’ viral markers; it was ﬁnally determined that he was
suffering from transfusion-transmitted hepatitis E.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
In Western countries, hepatitis E (HEV) testing is not currently
performed as part of the ﬁrst-line diagnosis for acute hepatitis,
mainly because HEV is still believed to be rare in developed coun-
tries unless the patient has recently travelled to an endemic area
where HEV-contaminated drinking water is the main source of
infection. However, indigenous cases of acute hepatitis E are
being increasingly reported, and most are caused by zoonotic
genotype 3 and 4 strains of HEV. The risk factors for these spo-
radic cases include shellﬁsh, contaminated animal meats (swine,
boar, deer), and direct contact with infected animals [1]. In addi-
tion, HEV prevalence in some industrialized countries is much
higher than might be expected: for example, in some French
regions, up to 52% of normal blood donors have serologic evi-
dence of past HEV infection [2].
We report here on the challenging clinical scenario of a
patient who presented with acute hepatitis while receiving
potentially hepatotoxic medications for autoimmune disorders,
with low-level autoimmune markers and negative ‘‘standard’’
viral markers; it was ﬁnally determined that he was suffering
from transfusion-transmitted hepatitis E.Journal of Hepatology 20
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E-mail address: anne-marie.roque@pbr.aphp.fr (A.-M. Roque-Afonso).An 81-year-old man presenting with ischemic heart disease,
chronic autoimmune thrombocytopenia and anemia was hospi-
talized in June 2011 for a worsening of his haematological dis-
ease. At admission, his liver enzymes were normal. He was
given corticosteroids (40 mg/day) and was then switched to
cyclosporine (75 mg twice daily) on June 22, 2011. In July 2011,
he presented with jaundice, elevated alanine aminotransferases
(ALT, 192 IU/L) and cholestasis (cGT, 144 and PAL, 65 IU/L). The
abdominal ultrasound and CT-scan were normal. Persistent cytol-
ysis led to the discontinuation of cyclosporine on August 30,
under the hypothesis of a drug-induced liver injury. However,
his aminotransferase levels did not improve, and meanwhile
the platelet count fell to 23,000/mm3. Eltrombopag (200 mg
three times daily) was then introduced on September 6. Three
weeks later, the patient’s cytolysis worsened (ALT 398 IU/L and
AST 673 IU/ml) (Fig. 1), requiring the discontinuation of
eltrombopag on September 27. Although the hepatic toxicity
of eltrombopag is well known, an initial etiological assessment
of the cytolysis was prescribed, including viral and autoimmune
markers. The markers of ongoing hepatitis A, B, and C were neg-
ative, and viremia of Epstein–Barr virus, cytomegalovirus, herpes
simplex viruses 1 and 2, varicella zoster virus and parvovirus B19
was undetectable. However, anti-smooth muscle (1/160) and
antinuclear antibodies (1/80, with speckled aspect) were found
to be weakly reactive, which prompted the reintroduction of cor-
ticosteroids (20 mg/day) under the hypothesis of autoimmune
hepatitis. On September 30, hepatitis E infection was diagnosed
with positive IgG and IgM (Adaltis, Milan, Italy) and detectable
HEV RNA (Ceeram, La Chapelle sur Erdre, France) with a 3f geno-
type. As immunosuppression could promote HEV persistence, the
corticosteroids were withdrawn. Liver enzyme levels returned to
normal on October 17 and HEV RNA was cleared in November.
Nevertheless, the patient’s anemia and thrombocytopenia wors-
ened, leading to decompensation of his cardiac disease with a
fatal outcome. A case review was then performed to elucidate
the origin of HEV transmission.
Analyses performed on stored sera revealed positive HEV RNA
and serology since June 30. The previous sample dated May 3 was
negative. We, therefore, estimated that contamination could have
occurred between early April and late June 2011. A zoonotic12 vol. 57 j 1374–1378
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Fig. 1. Evolution of transaminase levels according to time. Multiple transfu-
sions and eltrombopag administration are represented as black arrows and a dark
blue arrow, respectively. HEV RNA presence is indicated on the graph.
JOURNAL OF HEPATOLOGYtransmission via infected meat was unlikely since the patient did
not eat pork for religious reasons. In addition, no animal or envi-
ronmental exposure was recorded. Iatrogenic transmission was
then hypothesized because the patient had been hospitalized
several times since January 2011, and had received several trans-
fusions. Speciﬁcally, he received nine platelet concentrates and
four red blood cell units during the potential contamination per-
iod. This blood-transmission hypothesis was explored by testing
the blood donors involved in these transfusions. Twenty-eight
sera stored by the French Blood Agency (EFS) were tested for
HEV RNA. A single sample was positive with an estimated viral
load of 17,000 IU/ml (4.2 logIU/ml). This blood donation, together
with four others, were part of the platelet concentrate given to
the patient on April 19, ten weeks before the onset of hepatitis.
The donor’s HEV serology was negative; HEV sequencing based
on open reading frame two [3] and one [4] regions, identiﬁed a
genotype 3f strain (Fig. 2) presenting strict homology with the
patient’s strain. The donor was a 53-year-old woman, living in
a rural part of the Ile-de-France region (around Paris) and work-
ing as a secretary. As a regular donor, she was tested 6 months
later and presented with undetectable HEV RNA and serologic
evidence of past HEV infection. On examination, she reported
no symptoms, no travel, no contact with animals or other envi-
ronmental risk factors, but a habitual consumption of cured pork
products.Discussion
Transfusion-transmitted HEV infection was evidenced on the
basis of a strict sequence homology between the donor’s and
patient’s strain. Cyclosporine has occasionally been reported to
cause hepatitis, nevertheless, the ﬁrst ALT peak, initially attrib-
uted to drug toxicity, was certainly due to acute HEV infection.Journal of Hepatology 2012The second ALT peak occurred during the administration of a
drug well-known to be hepatotoxic. However, the persistent
HEV viremia observed in this immunocompromised patient
might have played a role. In line with this observation, a recent
report has shown that autochthonous hepatitis E might be mis-
diagnosed as drug-induced liver injury [5]. In this case, the
low-level detection of autoimmune markers was even more mis-
leading. Drug-induced liver injury and autoimmune hepatitis are
two challenging diagnoses that are reliant on excluding other
causes, including HEV. More generally, HEV infection should be
ruled out in all cases of acute hepatitis, even when no recent tra-
vel to endemic areas is reported; indeed, autochthonous HEV
infections are increasingly being reported [6] although the trans-
mission modes remain elusive in most cases. In our patient,
blood-borne transmission was hypothesized since the patient
had received multiple transfusions. And indeed, because it cannot
be inactivated in fresh blood products, hepatitis E virus poses a
risk to transfusion safety. Studies from endemic areas have
shown a higher prevalence of HEV markers in transfusion recip-
ients [7], and although such an association is not reported in
non-endemic areas, a few cases of transfusion-transmitted hepa-
titis E have been reported in Europe and Japan [8–10]. Severe
clinical forms of HEV infection can occur in immunocompro-
mised patients or those with underlying liver disease [11]. Never-
theless, in most cases, the infection may be subclinical, as
suggested by the unexpectedly high seroprevalence in some parts
of Western countries [2]. In South-West France, seroprevalence
increases with age, reaching 70% in people over the age of
58 years. The reasons for this extremely high rate are not clearly
understood, but may partly be related to dietary habits, which
include eating pork. This risk factor was not shared by our
patient, thus explaining the development of acute HEV at an
advanced age. The subclinical nature of most HEV infections
has also been highlighted by the detection of HEV viremia in a
signiﬁcant proportion of healthy blood donors with elevated
ALT in Japan [12–15]. In France, blood donors are not tested for
ALT, HEV antibodies or HEV RNA. Of note, in both the present case
and that reported by Colson et al. [9], only HEV RNA was detect-
able in the blood donation. The present report underlines the
need to improve our knowledge of HEV epidemiology in order
to guide transfusion safety policies in developed countries, and
highlights the need for HEV testing in the context of the ﬁrst-line
diagnosis of all cases of acute hepatitis.Financial support
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Fig. 2. Phylogenetic analysis of partial ORF2 and ORF1 regions. Phylogenetic trees were constructed on the MEGA4 software using the Neighbor-Joining method from a
Kimura 2-parameter distance matrix based on partial nucleotide sequences of ORF1 encoding for RdRp (323 nt) and ORF2 (315 nt). Bootstrap values obtained from 500
resamplings are shown. A 100% sequence homology is observed between blood donor and the recipient sequences. Genbank reference sequences are indicated by their
accession number.
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Fig. 2. (continued)
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